proteontm xpr 36 device (Bio-Rad)
Bio-Rad is a verified supplier 
Bio-Rad manufactures this product 
96
Structured Review
Bio-Rad
proteontm xpr 36 device
Proteontm Xpr 36 Device, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteontm+xpr+36+device/ProteOn+XPR36+Regulatory+Tools+Package/pm27729195-333-7-11
Average 96 stars, based on 1 article reviews
Proteontm Xpr 36 Device, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteontm+xpr+36+device/ProteOn+XPR36+Regulatory+Tools+Package/pm27729195-333-7-11
Average 96 stars, based on 1 article reviews
proteontm xpr 36 device - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Binding Assay:Article Title: Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors. Article Snippet: Accepted Manuscript Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors Stefanie Hauck, Kerstin Hiesinger, Sabrina Khageh Hosseini, Janosch Achenbach, Ricardo M. Biondi, Ewgenij Proschak, Martin Zörnig, Dalibor Odadzic PII: S0968-0896(16)30702-7 DOI: http://dx.doi.org/10.1016/j.bmc.2016.09.015 Reference: BMC 13268 To appear in: Bioorganic & Medicinal Chemistry Received Date: 6 June 2016 Revised Date: 13 August 2016 Accepted Date: 8 September 2016 Please cite this article as: Hauck, S., Hiesinger, K., Hosseini, S.K., Achenbach, J., Biondi, R.M., Proschak, E., Zörnig, M., Odadzic, D., Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors, Bioorganic & Medicinal Chemistry (2016), doi: http://dx.doi.org/10.1016/j.bmc.2016.09.015 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. |